Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)

NCT01286909 is registered in ClinicalTrials.gov with Omicron Pharmaceuticals as lead sponsor.

NCT NCT01286909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01286909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)
Lead sponsor
Omicron Pharmaceuticals
Phase
Phase 3
Overall status
Unknown status
Start date
January 31, 2011
Completion date
June 30, 2011
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic disease